Shire Pharmaceuticals Group's Acquisition of Biochem Pharma: Broadening Product Portfolio and Achieving Economies of Scale in Pharmaceuticals
9B03M034
-
- 1,99 €
-
- 1,99 €
Description de l’éditeur
Throughout the world, pharmaceutical companies were merging in order to achieve economies of scale in all of their activities, from research and product development through to distribution and marketing. While BioChem had several successful products and a track record of rapid expansion, nevertheless, in this new global environment it was now necessary for BioChem to achieve economies of scale through a consolidation of some type. The U.K. firm Shire was approximately the same size as BioChem, and faced the same dilemma. In a sense, Shire's acquisition of BioChem was a merger rather than a takeover and both corporations could achieve a unified global strategy that was beyond the means of each individually.
Plus de livres par David W. Conklin
Basel III: An Evaluation of New Banking Regulations
2010
Bombardier Versus Embraer: Charges of Unfair Competition
1999
India's Failure to Attract FDI
2006
Hugo Chavez's Public Policy Vision for Venezuela: Rooted in the Past, Doomed in the Future?
2006
Future of "Big Pharma?"
2005
Privatizing Poland's Telecom Industry: Opportunities and Challenges in the New Economy and e-Business (B)
2008